DCprime (spin-off VUmc) announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia. This administration marks the official start of the phase 2 study in the ADVANCE-II study. A total of 20 patients with acute myeloid leukemia (AML), a rare form of leukemia, participate in this study. A recently completed phase I study showed that the cancer drug DCP-001, a vaccine based on dendritic cells, is generally safe and capable of triggering an anti-cancer immune response in patients with AML.
Read here the full press release.
Photosynthetic & Veridis, two VU start-ups, are part of the Pole Position Programme #4 by Techleap. Through the programme, like-minded industry experts who will guide the founders of Photosynthetic & Veridis on their journey towards becoming global leaders and take Pole Position. Techleap is a government funded organization to connect and empower startups to grow and sustain a productive tech community.
NewsPhlox, a private biotechnology spin-off from Amsterdam UMC and specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead program aimed at rare genetic laminopathies.
NewsPanel B.V., a spin-off from the University of Amsterdam, has received a loan from the Innovatiefonds Noord-Holland. This loan will enable Panel to continue building its innovative tool for inclusive participation processes. The unique method was designed by sociologists Gerben Moerman and Christiaan Bröer of the UvA Faculty of Social and Behavioural Sciences. The method […]
News